Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
Charles S. Haworth, Michal Shteinberg, Kevin Winthrop, Alan Barker, Francesco Blasi, Katerina Dimakou, Lucy C. Morgan, Anne E. O'Donnell, Felix C. Ringshausen, Oriol Sibila, Rachel M. Thomson, Kevin J. Carroll, Federica Pontenani, Paola Castellani, James D. Chalmers
Dive into the research topics of 'Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months'. Together they form a unique fingerprint.